Emma Walmsley, GlaxoSmithKline CEO (GSK via investor day livestream)
November 8, 2021 07:27 AM EST
R&D

Steer­ing clear of Fi­bro­Gen/As­traZeneca wreck­age, Glax­o­SmithK­line spot­lights piv­otal da­ta for star ane­mia drug

Amber Tong

We now know ex­act­ly what Glax­o­SmithK­line will be tak­ing to the FDA and EMA as it pitch­es its oral ane­mia drug for pa­tients with chron­ic …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times